ATP5PD

Across TCGA pan-cancer cohorts, ATP5PD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP5PD data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP5PD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5PD expression acts as an unfavorable survival marker, although some lineages such as OV and CCRCC show a favorable association.

LUAD, OV, and CCRCC are the cancer types where ATP5PD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.484	0.787	.005	24	view →
OV	DFS	Median	All	0.910	0.550	.040	4	view →
CCRCC	OS	Quartile	III,IV	0.905	0.523	.007	3	view →
GBM	OS	Median	All	0.872	0.760	.031	2	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.852	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP5PD–LUAD (DFS)

Open the LUAD breakdown →